Plk1 a potential target for cancer therapy
Webb16 mars 2024 · RNA interference (RNAi), also known as gene silencing, is a biological process that prevents gene expression in certain diseases such as cancer. It can be used to improve the accuracy, efficiency, and stability of treatments, particularly genetic therapies. However, challenges such as delivery of oligonucleotide drug to less … Webb5 juli 2016 · Plk1 in Therapy Resistance Likely because of its central role in cell-cycle progression and other cellular processes such as the DNA damage pathway, Plk1 has …
Plk1 a potential target for cancer therapy
Did you know?
Webb10 dec. 2012 · Polo-like kinase 1 (Plk1) is an interesting molecule both as a biomarker and as a target for highly specific cancer therapy for several reasons. Firstly, it is over-expressed in many cancers and can serve as a biomarker to monitor treatment efficacy of Plk1 inhibitors. Furthermore, the Plk1 enzyme is expressed only in dividing cells and is a … Webb13 apr. 2024 · Understanding the mechanism of action of rigosertib has potential clinical implications worth exploring, as it may help to tailor cancer therapies and improve patient outcomes. First , rigosertib was described as an inhibitor of the mitotic master regulator Polo-like kinase 1 (Plk1).
Webb17 feb. 2024 · The key role of Wee1 in regulating the G2/M checkpoint in response to DNA damage has made it an attractive target for cancer therapy. ... to AZD1775, which at higher concentrations also inhibits PLK1, ... Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy. PloS One (2012) 7(6):e38254. doi: 10 ... Webb17 maj 2024 · Its best documented role is in cancer, ... and the residual phosphorylation is not sensitive to a specific PLK1-3 inhibitor, ... proposing this kinase as a possible target for DM therapy. 253 ...
Webb1 aug. 2004 · Otherwise, Polo-like kinase 1 (PLK1) plays a key role in mitotic progression and cell-cycle control [37], which is confirmed to be one of the potential drug targets for cancer therapy [38]. Webb10 dec. 2012 · Polo-like kinase 1 as target for cancer therapy Exp Hematol Oncol. 2012 Dec 10;1 (1):38. doi: 10.1186/2162-3619-1-38. Authors Lily Weiß 1 , Thomas Efferth …
WebbPLK1-based combination therapies have shown increased apoptosis, disrupted cell cycle, and potential to overcome resistance in cancer cells/tissues over monotherapies. …
Webb2 nov. 2016 · plk1, a potential target for cancer therapy Authors: Zhixian Liu Nanjing Medical University No file available ResearchGate has not been able to resolve any … primary sassoon font downloadWebb1 feb. 2024 · Xiaosheng Wang Abstract and Figures Polo-like kinase 1 (PLK1) plays an important role in the initiation, maintenance, and completion of mitosis. Dysfunction of … primary sample ballot pasco countyWebbThus, PLK1 is expected to be a potential target for cancer therapy. In this article, we examined PLK1’s structural characteristics, its regulatory roles in cell mitosis, PLK1 … primary sanctions us nexusWebb14 okt. 2011 · This review describes inhibitors of a regulator of mitotic spindle formation, Polo-like kinase 1 (Plk1), introduces the rationale for targeting Plk1 in cancer therapy, and discusses preclinical and early clinical data from studies of Plk1 inhibitors, with a particular focus on non–small cell lung cancer (NSCLC). primary samplerWebb27 feb. 2024 · Rigosertib (ON-01910.Na) is a small-molecule member of the novel synthetic benzyl-styryl-sulfonate family. It is currently in phase III clinical trials for several myelodysplastic syndromes and leukemias and is therefore close to clinical translation. The clinical progress of rigosertib has been hampered by a lack of understanding of its … primary sap schoolsWebb14 jan. 2010 · In summary, Plk1 seems to be an appealing target for cancer therapy, however, further evaluation is necessary to discern the utility of Plk1 inhibitors in a … primary samplers lsa 350Webb27 feb. 2024 · Rigosertib (ON-01910.Na) is a small-molecule member of the novel synthetic benzyl-styryl-sulfonate family. It is currently in phase III clinical trials for several … primary sassoon font free